Good
Mostly Aligned
Patient Risk:
Moderate
Summary
Most safety and indications claims align with the provided FDA label excerpts, including the requirement for direct supervision and at least 2 hours of post-dose monitoring. Several financial/access claims (pricing, savings program details) are not supported by the supplied prescribing information excerpts and therefore reduce alignment.
Category Scores
Accurate Statements
Spravato is administered under the direct supervision of a healthcare provider in a healthcare setting.
2 Dosage and Administration: “must be administered under the direct supervision of a healthcare provider.”
Spravato administration requires post-administration observation at each treatment session.
2 Dosage and Administration: “post-administration observation under supervision” and boxed-warning cross-references.
Patients must be monitored for at least 2 hours after administration at each treatment session until clinically stable and safe to leave.
2 Dosage and Administration and Warnings/Boxed Warning cross-references: “Monitor patients… for at least 2 hours…” and “observe… for at least 2 hours until… safe to leave.”
SPRAVATO may cause sedation/loss of consciousness and requires monitoring due to delayed/prolonged sedation.
5.1 Sedation.
SPRAVATO can cause dissociation/perceptual changes and requires monitoring.
5.2 Dissociation and monitoring requirement at least 2 hours.
SPRAVATO can increase risk related to respiratory depression and requires monitoring (including pulse oximetry) for at least 2 hours.
5.3 Respiratory Depression and 2 Dosage and Administration: “including pulse oximetry… for at least 2 hours.”
SPRAVATO has potential for abuse/misuse and is only available through a restricted REMS program.
5.4 Abuse and Misuse and 5.5 REMS.
Increased risk of suicidal thoughts/behaviors in adolescents and young adults is described for antidepressants; SPRAVATO is not approved for pediatric patients.
5.6 Suicidal Thoughts and Behaviors in Adolescents and Young Adults (including: “not approved for pediatric patients”).
Spravato is indicated for treatment-resistant depression (TRD) in adults as monotherapy or in conjunction with an oral antidepressant.
1 Indications and Usage.
Spravato is indicated for depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant.
1 Indications and Usage.
Unsupported Statements
The list price for Spravato is approximately $600 per treatment.
Not supported in the provided FDA prescribing information excerpts.
Janssen Pharmaceutical Companies offers a savings program for Spravato.
Not supported in the provided FDA prescribing information excerpts.
For eligible commercially insured patients, the out-of-pocket cost could be as low as $0 for the medication per month.
Not supported in the provided FDA prescribing information excerpts.
The savings program has a maximum annual out-of-pocket spending limit.
Not supported in the provided FDA prescribing information excerpts.
The savings program is managed by the Janssen CarePath program.
Not supported in the provided FDA prescribing information excerpts.
Coverage for Spravato varies among insurance providers.
Not supported in the provided FDA prescribing information excerpts.
Many insurance plans may require prior authorization for Spravato coverage.
Not supported in the provided FDA prescribing information excerpts.
Many insurance plans may have specific criteria that must be met for Spravato coverage.
Not supported in the provided FDA prescribing information excerpts.
Spravato can increase blood pressure.
Not supported by the provided label excerpts (sedation/dissociation/respiratory depression/abuse/suicidality sections cited in the prompt).
Increased blood pressure with Spravato requires monitoring.
Not supported by the provided label excerpts.
Spravato is a non-MAO antidepressant.
Not supported by the provided label excerpts.
Spravato works differently from traditional antidepressants.
Not supported by the provided label excerpts.
Spravato is thought to rapidly increase levels of glutamate.
Not supported by the provided label excerpts.
Spravato is thought to help quickly restore synaptic connections in the brain.
Not supported by the provided label excerpts.
In the context provided, restoring synaptic connections improves mood.
Not supported by the provided label excerpts.
In the context provided, improving mood helps reduce suicidal thoughts.
Not supported by the provided label excerpts.
Contradictions
Important Omissions
Exact REMS restricted dispensing/REMS program details beyond general restricted availability (e.g., that it is available only through a restricted program under REMS) were not clearly specified by the claims, though the general concept was mentioned.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Moderate
Safety-related claims about required healthcare-provider supervision and at least 2-hour monitoring for sedation/dissociation/respiratory depression are label-supported. However, additional unsupported mechanism/indication-adjacent statements and unsupported blood pressure/monitoring claims could mislead readers about risks or required monitoring specifics.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Multiple non-label claims (pricing, savings program details, insurance coverage/prior authorization, mechanism statements, and blood-pressure statements) were not supported by the provided FDA label excerpts.
Suggested Improvement
Limit claims to the provided label-supported content (direct supervision; at least 2-hour monitoring; sedation/dissociation/respiratory depression and abuse/misuse and REMS; indicated populations/conditions). Remove or re-verify all pricing, savings-program, insurance-access, mechanism, and blood-pressure/monitoring statements against label-supported text.